Inhibitors of HMG-CoA Reductase: Current and Future Prospects

Mini Rev Med Chem. 2009 Oct;9(11):1272-83. doi: 10.2174/138955709789878105.

Abstract

High levels of cholesterol are a primary risk factor in the development of cardiovascular diseases. In this review, we have summarized the structural, chemical and computational aspects of hypocholesterolemic drugs, both statins and non-statins, that target enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) to block cholesterol biosynthesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Allylbenzene Derivatives
  • Anisoles / chemistry
  • Anisoles / pharmacology
  • Anticholesteremic Agents / chemistry*
  • Anticholesteremic Agents / pharmacology
  • Binding Sites
  • Cardiovascular Diseases / drug therapy
  • Cholesterol / metabolism
  • Databases, Protein
  • Humans
  • Hydroxymethylglutaryl CoA Reductases / chemistry*
  • Hydroxymethylglutaryl CoA Reductases / metabolism
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / chemistry*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Lipoproteins, LDL / metabolism
  • Structure-Activity Relationship

Substances

  • Allylbenzene Derivatives
  • Anisoles
  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Lipoproteins, LDL
  • asarone
  • Cholesterol
  • Hydroxymethylglutaryl CoA Reductases